Drug intelligence / Profile preview

COVID-19 vaccine + influenza vaccine

Development stage: Phase 2
Lead developer: BioNTech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Combination vaccines for COVID-19 and influenza are designed to provide simultaneous protection against SARS-CoV-2 and seasonal influenza viruses in a single administration. These products aim to improve vaccination uptake and reduce the burden on healthcare systems by streamlining immunization schedules. Major development programs utilize diverse technologies, including messenger RNA (mRNA) platforms (e.g., BioNTech/Pfizer, GSK/CureVac, and Moderna) and recombinant protein subunit platforms with adjuvants (e.g., Sanofi/Novavax). The vaccines typically target the SARS-CoV-2 spike protein alongside hemagglutinin (HA) antigens from multiple influenza A and B strains. Clinical trials focus on demonstrating that the combination does not compromise the immunogenicity of either component compared to standalone vaccines while maintaining a safety profile consistent with established respiratory vaccines.

Brand names: No established brand names as of September 2025
Other names: COVID-19-influenza combination vaccineCOVID19-influenza combination vaccineCOVID 19-influenza combination vaccineCOVID-Influenza Combination vaccineCIC vaccineCOVID-19/Flu combination vaccine

Targets

SARS-CoV-2 spikeHA (Hemagglutinin)Neuraminidase

Beyond the preview

Go deeper on COVID-19 vaccine + influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVID-19 vaccine + influenza vaccine.

Explore the full profile